Compare iShares China Large-Cap ETF (FXI) vs UiPath Inc (PATH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
iShares China Large-Cap ETF vs UiPath Inc — how do they compare? iShares China Large-Cap ETF trades at $33.93 (market cap $3.90B), while UiPath Inc trades at $13.33 (market cap $6.81B). The key difference: UiPath Inc is the larger of the two by market cap, and UiPath Inc is trading nearer its 52-week high, iShares China Large-Cap ETF nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold iShares China Large-Cap ETF for 149 Days and UiPath Inc for 139 Days on average.
| FXI | PATH | |
|---|---|---|
Market Cap | $3.90B | $6.81B |
Volume | 16,526,479 | 22,766,109 |
52-Week High | $41.08 | $19.29 |
52-Week Low | $31.59 | $9.38 |
Typical Hold Time | 149 Days | 139 Days |
Sector | — | Technology |
Enterprise Value | — | $5.61B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
FXI (iShares China Large-Cap ETF) trades at $33.42, down 1.04% with a bearish technical outlook. The ETF shows compelling valuation at half the S&P 500's P/E ratio with a 1.98% yield, but faces headwinds from China's economic challenges and geopolitical tensions. Recent corporate profit growth of 26% in Q2 2026 provides fundamental support, though weak momentum persists amid global trade concerns.
The ETF offers diversification value and valuation appeal but carries significant political and economic risks. China's industrial overcapacity and weak domestic consumption create volatility, while U.S.-China relations remain a key variable. Institutional interest focuses on long-term value despite near-term bearish technical signals.
UiPath (PATH) trades at $13.07, down 0.23% on the day, amid a bearish technical signal and mixed earnings history. The company shows improving fundamentals with revenue growing from $1.43B in 2025 to a projected $1.7B in 2026, while net income is expected to turn positive. Recent news highlights AI partnerships and product innovations, but the stock faces headwinds from cautious analyst sentiment and technical resistance.
The outlook for PATH is cautiously optimistic, with strong revenue growth and a path to profitability offering upside potential, but risks include execution challenges and competitive pressures. The consensus price target of $15.13 suggests moderate upside from current levels, though investor sentiment remains divided.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About iShares China Large-Cap ETF
The fund generally will invest at least 80% of its assets in the component securities of its underlying index and in investments that have economic characteristics that are substantially identical to the component securities of its underlying index. The index designed to measure the performance of the largest companies in the Chinese equity market that trade on the Stock Exchange of Hong Kong and are available to international investors. The fund is non-diversified.
Read more on FXI →About UiPath Inc
UiPath Inc creates an end-to-end platform that provides automation with user emulation at its core. Its platform is built to be used by employees throughout a company and to address a wide variety of use cases, from simple tasks to long-running, complex business processes. It generates revenue from the sale of licenses for its proprietary software, maintenance and support, and professional services. It generates a majority of the revenues from the US, followed by Romania and the rest of the world.
Read more on PATH →
